2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

5411 Zanubrutinib plus R–CHOP or R–PolaCHP in newly diagnosed diffuse large B-cell lymphoma (DLBCL): Final results from a phase 1b trial

Yazeed Sawalha, MD, Ying Huang, MA, MS2, Brian Hess, MD3, Kathryn Lurain, MD, MPH4, Audrey Sigmund, MD5, Timothy J Voorhees, MD,MSc6, David Bond, MD, BS7, John Reneau, MD, PhD8, Katherine Antel, MD9, Taylor R. Brooks, MD10, Paolo Fabrizio Caimi, MD11, Beth Christian, MD12, Robert A Baiocchi, MD, PhD13, Lapo Alinari, MD, PhD14, Kami Maddocks, MD15, Brian Hill, MD, PhD16
1 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
2 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3 Hollings Cancer Center of the Medical University of South Carolina, Charleston, United States
4 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
5 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
6 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
7 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
8 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
9 Hollings Cancer Center of the Medical University of South Carolina, Charleston, United States
10 Cleveland Clinic, Cleveland, United States
11 Cleveland Clinic, Cleveland, United States
12 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
13 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
14 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
15 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
16 Cleveland Clinic, Cleveland, United States

Introduction

Several studies suggest a therapeutic role for BTK inhibitors in DLBCL. In the PHOENIX trial, adding ibrutinib to R-CHOP improved outcomes only in patients (pts) <60 years, an age-based discrepancy attributed to increased toxicity and reduced R-CHOP dose intensity in older pts. We hypothesized that zanubrutinib (zanu) - a BTK inhibitor with greater selectivity and improved safety - could be safely combined with R-CHOP or R-PolaCHP. We conducted a phase Ib investigator-initiated trial (NCT04850495) across 3 US centers that evaluated zanu plus R-CHOP (ZaR-CHOP) and zanu plus polatuzumab vedotin with R-CHP (ZaR-PolaCHP). We report final study results, including updated efficacy for ZaR-CHOP (safety reported at ASH 2023) and safety/efficacy data for ZaR-PolaCHP.

Methods

Eligible pts had newly diagnosed DLBCL irrespective of cell-of-origin (COO), an International Prognostic Index (IPI) ≥2 (≥1 for ZaR-CHOP), and required 6 cycles of treatment (tx). Pts received standard-dose R-CHOP or R-PolaCHP (Day 1) and zanu (Days 1–21) in 21-day cycles for 6 cycles. A dose de-escalation design was used to determine the recommended phase 2 dose (RP2D). One pre-enrollment cycle of R-CHOP/R-PolaCHP was permitted. Primary objectives were to evaluate safety and establish the RP2D of ZaR-PolaCHP. Secondary objectives were to evaluate overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and tx exposure. The database was locked for analysis on 6/24/2026.

Results

From 10/2021 to 5/2023, 14 pts received ZaR-CHOP. Median age was 59 years (range, 23–74); 6 (43%) were >60 years. Six (43%) had IPI ≥3. COO (Hans criteria) was germinal center B-cell (GCB) in 7 (50%) and non-GCB in 7 (50%). Median time from diagnosis to tx was 18 days (range, 5–52). No dose-limiting toxicities (DLTs) occurred; zanu 160 mg BID was determined as the RP2D. For response-evaluable pts (n=13), end-of-treatment (EOT) ORR and complete response rate (CRR) were both 92.3%. At a median follow-up of 40 months, 3 pts developed disease progression (PD; 2 GCB, 1 non-GCB). The 1- and 3-year PFS rates were 84.6% (95% CI, 51.2–95.9%) and 76.2% (95% CI, 42.7–91.7%); 3-year OS was 100%.

From 5/2024 to 6/2026, 24 pts received ZaR-PolaCHP. Median age was 63 years (range, 29–75); 16 (67%) were >60 and 8 (33%) ≥70 years. Fourteen (58%) had IPI≥3. COO was GCB in 8 (33%) and non-GCB in 16 (67%). Median time from diagnosis to tx was 22 days (range, 5–58). Seventeen pts (71%) received 1 pre-enrollment cycle of R-CHOP or R-PolaCHP. One DLT (tx delay) occurred; zanu 160 mg BID was selected as the RP2D. Four pts (17%) discontinued tx on trial prematurely (2 of whom continued tx off trial) due to: cytopenias/consent withdrawal (n=1), rituximab-related pneumonitis (n=1), recurrent grade (G) 3/4 infection and G4 thrombocytopenia (n=1), and logistical tx delays (n=1). Relative dose intensities for cyclophosphamide and doxorubicin were ≥90% in 96% and 100% of pts, respectively. Five pts (21%) required zanu dose reductions: G3 hematuria, n=2; G3 infection/G4 thrombocytopenia, n=1; G3 infection, n=1; G4 thrombocytopenia, n=1.

The most frequent (≥30%) any-grade tx-related adverse events (TRAEs) for ZaR-PolaCHP were peripheral neuropathy (58%), fatigue (54%), diarrhea (38%), nausea (38%), and mucositis (33%). G≥3 TRAEs (n=1 [4%] each, unless noted) were neutropenia (n=2, 8%), hematuria/non-infectious cystitis (n=2, 8%), diarrhea, anemia, thrombocytopenia, hypertension, upper respiratory infection, febrile neutropenia (FN), abdominal pain, diverticulitis, cellulitis, lymphopenia, syncope, and pneumonitis. Serious AEs occurred in 6 pts (24%), most frequently FN and/or infection (n=3, 13%). No G5 TRAEs occurred.

For response-evaluable pts (n=22) on ZaR-PolaCHP, EOT ORR and CRR were 100% and 95.5% (1 partial response converted to CR after radiation). Two pts developed PD, both with isolated central nervous system (CNS) involvement (both non-GCB). One pt died while in CR from glioblastoma. At a median follow-up of 10 months (range, 2–24), the 1-year PFS and OS rates were 80.7% (95% CI, 51.1–93.4%) and 93.3% (95% CI, 61.3–99.0%).

Conclusions

Incorporating zanu into frontline R-CHOP and R-PolaCHP regimens is safe and does not compromise tx dose intensity or delivery. High CRR and prolonged PFS were observed, although CNS relapses were not eliminated.  These data support further study of zanu-based frontline combinations in DLBCL.

Yazeed Sawalha, MD: BeOne - Research Funding; AbbVie - Research Funding; Genmab - Research Funding; BeOne - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); ADC - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)